DYNE THERAPEUTICS INC. - COMMON STOCK

Dyne Therapeutics Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

25 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Chief Scientific Officer Transition

02 Jun 2021 16:05:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference

26 May 2021 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Demonstrating Sustained Knockdown of Toxic Human Nuclear DMPK RNA

14 May 2021 07:00:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

06 May 2021 07:29:00 By Nasdaq GlobeNewswire

New Preclinical Data from Dyne Therapeutics’ Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual Meeting

27 Apr 2021 16:35:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights

04 Mar 2021 07:35:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer

04 Mar 2021 07:25:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs

08 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Pricing of $168 Million Public Offering

20 Jan 2021 20:05:29 By Nasdaq GlobeNewswire

Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study

10 Jan 2021 15:00:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

05 Jan 2021 07:30:00 By Nasdaq GlobeNewswire